Biomarkers: Market Research Report

Date: August 22, 2011
Pages: 1305
Price:
US$ 4,800.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B0ACF7C2E29EN
Leaflet:

Download PDF Leaflet

Biomarkers: Market Research Report
This report analyzes the worldwide markets for Biomarkers in US$ Million by the following Technologies and Services: Technologies - Emerging Biomarker Technologies (Imaging biomarkers, Proteomics, Transcriptomics, & Bioinformatics), Conventional Biomarker Technologies - (Immunodiagnostics, & Molecular Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others).

The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular).

Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2008 through 2017.

The report profiles 204 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Alexion Pharmaceuticals, Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux, Bruker Corporation, Caprion Proteomics, Inc., Clarient Inc., Compugen, Ltd., Correlogic Systems, Inc., DiagnoCure, Inc., Epigenomics AG, GE Healthcare, Gene Logic, Genedata AG, Gen-Probe Inc., GlaxoSmithKline Plc, Hitachi Medical Corporation, Illumina, Inc., LabCorp., Life Technologies Corporation, Merck & Co. Inc., Metabolon, Inc., Myriad Genetics, Inc., Novartis International AG, Panacea Laboratories, Pfizer, Inc., Philips Healthcare, QIAGEN NV, Quest Diagnostic, Inc., Quest Diagnostics Company, Roche Diagnostics Corp., Rubicon Genomics, Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
Definitions
Biomarker Technologies
Emerging Biomarker Technologies
Proteomics
Transcriptomics
Imaging biomarkers
Bioinformatics
Conventional Biomarker Technologies
Molecular Diagnostics
Immunodiagnostics
Other Biomarker Technologies
Metabolite and Enzyme Assays
Reagents
Biomarker Services
Clinical Biomarker Services
Biomarker Testing
Assay Development and Production
Antibody Development
Specimen Preparation
Bioinformatics and Others

2.INDUSTRY OVERVIEW

Global Biomarkers Market Surges in the Backdrop of Widening Medical Scope and Applications
Factors Engendering Positive Vibes
Factors Engendering Positive Influence on the Biomarkers Market: A Summary
Biomarkers: A Regional Perspective
US Spearheads the Global Biomarkers Market
US and Japan Take Lead on the Patent Front

Table 1. Dominance of US in the Global Biomarker Patent Filings (includes corresponding Graph/Chart)
Table 2. Leading Players in the Biomarkers Space by Number of Patent Filings (includes corresponding Graph/Chart)
Table 3. Number of Biomarker Patents Published and Filed: 2003-2007 (includes corresponding Graph/Chart)

Asia-Pacific: The Fastest Growing Biomarker Market
Supportive Governments and Regulatory Bodies to Fuel Growth
Increasing Collaborations Among Regulators and Companies Augur Well for Biomarkers
Player Strategies: An Insight

Table 4. Growing Number of Biomarker Deals (includes corresponding Graph/Chart)
Table 5. Competitive Strategy Mix in the Global Oncology Biomarkers Market (includes corresponding Graph/Chart)

Pharma and Biomarker Developer Tie-Ups to Raise Drug Development Productivity

3.MARKET OUTLOOK

Biomarkers: Evolving Scope and Applications
Technological Advancements – A Boon for Biomarker Discovery
Evolving Role of Biomarkers in Drug Development
Companion Biomarkers
Biomarkers Play Invaluable Role in Oncology and Cardiovascular Disease Diagnosis
Personalized Medicine- Revolutionizing the Medical Treatment
Biomarker-Led Drug Discovery – A ProfiTable Investment
Technological Trends
Proteins Gain Upper Hand in Biomarkers
Mass Spectrometry – A Promising Technology in Molecular Medicine
Market Restraints
Challenges in Biomarker Validation – A Major Growth Retardant
The Road Ahead
Biomarkers to Witness Significant Growth in Therapeutic and Diagnostic Arenas
Efficiency Improvements Must for Realizing Cost-Effective Biomarker Testing

4.BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW

Biomarker – Definition & Introduction

BIOMARKER TECHNOLOGIES

EMERGING BIOMARKER TECHNOLOGIES

Proteomics
Growth Drivers and Market Trends
Efficiency Gains in Drug Discovery Drive Growth in Proteomics
Proteomics Witness Increased Focus on Targeted Approach
Mass Spectrometry –Shifts in Focus to Proteomics Helps Biomarker Development
Mass Spectrometry Expands Scope of Protein Biomarker Applications
Transcriptomics
Transcriptomics – Assisting in Identification of Biomarkers
Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way
Types of Imaging Biomarkers – An Overview
Market Trends
Molecular Imaging - Gaining Importance in Drug Discovery and Development
Use of Molecular Imaging in Clinical Trials for Drug Development
Bioinformatics

CONVENTIONAL BIOMARKER TECHNOLOGIES

Molecular Diagnostics
Immunodiagnostics
Market Trends
Growth in Use of Molecular Diagnostics to Propel Biomarker Growth
Demand for Novel Biomarkers Persists in Immunodiagnostics
Immunoassays Plagued with Standardization Issues

OTHER BIOMARKER TECHNOLOGIES

Metabolite and Enzyme Assays
Reagents
Market Trends
Microarrays Surge Biomarker Identification
Metabolomics Gain Rapid Foothold in Drug Discovery

BIOMARKER SERVICES

Expanding Capabilities Drive Large-Scale Adoption
Clinical Biomarker Services
Biomarker Testing
Assay Development and Production
Antibody Development
Specimen Preparation
Bioinformatics and Other Biomarker Services
Bioinformatics Gain Prominence
miRNA Analysis
Microarray Services Witness Increasing Investments

5.BIOMARKERS MARKET BY APPLICATION

Role of Biomarkers in Drug Discovery and Development
Role of Biomarkers in Clinical Research and Patient Management
Major Benefits of Biomarkers in Clinical Development
Major Benefits of Biomarkers in Medicine
Multifarious Applications of Biomarkers
New Applications Come to the Fore
Application of Biomarkers in Drug Development
Herceptin and Vilazodone –References for Success of Biomarker Based Approach
Increasing Role of Biomarkers in Modern Drug R&D
Translational Medicine Biomarkers Revolutionizing Drug Development Process
Outsourcing - Opportunities Galore
CROs in a Dilemma Over Investments in Biomarker Analysis Services
Lower Productivity of Traditional Drug Discovery Approach Calls for New Methods
Blockbuster Model Versus Personalized Medication Model
Workflow Standardization – Key to Success of Biomarkers in Drug Development

6.BIOMARKERS BY THERAPEUTIC AREA

Current & Future Analysis

ONCOLOGY

Factors Driving Oncology Biomarkers’ Growth
US Remains at the Forefront of Cancer Biomarker Patent Filings

Table 6. Regional Split in the Global Cancer Biomarker Patent Filings: 2009 (includes corresponding Graph/Chart)
Table 7. Leading Players in Cancer Biomarkers by Number of Patent Filings: 2004-2009

Global Oncology Diagnostics and Drug Discovery Biomarkers Market

Table 8. World Recent Past, Current and Future Analysis for Oncology Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 9. World 10-Year Perspective for Oncology Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 10. Global Cancer Biomarkers Diagnostics (Molecular) Market by Company (2009): Market Share Breakdown of Revenues for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others (includes corresponding Graph/Chart)

Evolution of Oncology Biomarkers
Available and Pipeline Biomarkers in Various Cancers
Breast Cancer Dominates Cancer Biomarkers Pipeline

Table 11. Global Cancer Biomarkers Pipeline by Indication (2010): Percentage Share Breakdown for Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and Others (includes corresponding Graph/Chart)
Table 12. Global Oncology Biomarkers Market: Percentage Breakdown of Patent Filings by Oncology Area (2007)

Breast Cancer Market Awaits New Specific Biomarkers
Oncology Biomarker Diagnostic Techniques

Table 13. Leading Cancer Biomarker Diagnostic Technologies (2009): Percentage Share of Value Sales for Gene-based Markers, Proteomics, DNA Microarrays, Immunological Markers and IHC Tests, and Others (includes corresponding Graph/Chart)

Current Trends in Cancer Biomarkers
Validation Techniques Take Center Stage
Early-Stage Use of Biomarkers High in Oncology
Proteomics Ahead of Genomic Biomarkers in Functionality
Pharmacogenomics and IHC Tests Inch Ahead in Cancer Biomarker Diagnostics
Faster Diagnosis Benefits DNA Microarray Technology
Other Tests Lose Market Share
Companion Biomarkers in Oncology

CARDIOLOGY

Market Trends
Increasing Health Burden Drives Research Efforts
Gene Expression Analysis Delivers Novel Therapeutic Approaches
High-Performance Techniques Drive Biomarker Discovery in Cardiology
Effective Phenotyping Takes Precedence for Successful Genotyping Studies
Role of Linkage Analysis in Cardiovascular Biomarker Identification
Biomarkers of ACS
Biomarkers – A Promising Diagnostic Tool for ACS
Biomarker Discovery in Cardiovascular Diseases to Undergo Significant Changes
Major Cardiovascular Diagnostic Biomarkers – A Focus on Biomarkers for ACS
Creatine Kinase-Myocardial Band
Natriuretic Peptides
Cardiac Troponin
Myoglobin
New Diagnostic Biomarkers for ACS on the Anvil
Genomic Biomarkers for Detecting Cardiovascular Diseases
Growing Demand for Stroke Biomarkers
Rising Incidence of the Disease – A Major Driver for Stroke Biomarkers

CENTRAL NERVOUS SYSTEM (CNS)

Lower Commercial Availability Restricts Market Share
Research Efforts Remain Confined to Specific Areas
High Cost of Treatment Shadows Biomarkers’ Short-Treatment Benefits
Research Methodology in CNS Biomarkers
Alliances – A Key Aspect to the Development of CNS Biomarkers
Biomarkers in Select CNS Diseases
Alzheimer's Disease
Parkinson's Disease Biomarkers - Crucial for Neuroprotectants’ Effectiveness
Schizophrenia: An Unexploited Segment

OTHER THERAPEUTIC AREAS

Inflammatory and Autoimmune Disorders
Biomarkers offer Efficient Diagnosis and Treatment
Rheumatology

7.AN OVERVIEW OF SELECT BIOMARKERS

HER2/neu/ ErbB2 Gene
HER2 and its Association with Cancer
Target Drugs for HER2
Hepsin Biomarkers
Early Prostate Cancer Antigen-2

MMP-3

ImmunoCyt™/uCyt+™
AmpliChip CYP450 Test
The OncoVue® Breast Cancer Risk Test
Oncotype DX® Test
Oncotype DX Colon Cancer Assay
MammaPrint
Theros CancerTYPE ID
PgxPredict:CLOZAPINE– Test for Qualifying Patients to Use Clozapine
The Pathwork Tissue of Origin Test
PROGENSA PCA3 Assay
Epi proColon® Early Detection Assay
OVA1® Test
Bcr-abl Fusion Protein

HLA-B

Mammostrat®
Ipsogen MapQuant Dx™ Genomic Grade
CA1-18 Enzyme Immunoassay (EIA)
Anti-L523S Antibody

8.PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE

RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker Tests
Avantra Introduces New BioChip Immunoassay Biomarker Workstation
Clarient Introduces Mammostrat Test
Biomagnetics Diagnostics Identifies Second Biomarker for Tuberculosis Assay
Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay
Crescendo Bioscience Launches New Multi Biomarker Blood Test
Alere International Launches New Triage® NT-proBNP Test
Agilent Technologies Launches New SureSelect Kinome Target Enrichment Kit
Roche Diagnostics to Launch New STAT Immunoassays
Gentel Biosciences Launches New Human Profiling Kits
QIAGEN Introduces QIAsymphony RGQ System
Almac Introduces Biomarkers for Biopharmaceutical Industry
i-Path Introduces TMA Toolbox
Abbott Introduces ARCHITECTPLUS Systems
Affymetrix Introduces QuantiGene® ViewRNA Assayformats
ARUP Laboratories Introduces New Test for Colorectal Caner Detection
Warnex Launches Blood Testing Service for Colorectal Cancer in Canada
Agilent Technologies Launches mAb-Glyco-Chip
synlab Launches Septin9 Testing in Germany
IDBS Introduces New Biomarker Discovery and Validation Solution
Quest Diagnostics Introduces Blood Test for Detecting Colorectal Cancer
Clarient Introduces Biomarker Panel for NSCLC Classification
Institute of Microelectronics and Agency for Science, Technology and Research Launch Rapid Cardiac Biomarker Test
Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment
Thermo Fisher Introduces New Copeptin Assay
Psynova Neurotech and RBM Identify New Biomarkers for Schizophrenia
Genedata Unveils Genedata Expressionist® 5.3
Arrayit Introduces Biomarker Discovery Service
Invitrogen Introduces Biomarker Tool for Kidney Function Research
Abbott Introduces ARCHITECT® c4000®
Epigenomics Rolls Out Epi proColon Range in Europe
Genedata Introduces Expressionist 5.2 for Identifying MS-based Biomarker
VisEn Unveils FAST – A Novel Imaging Platform
Millipore and CXR Biosciences Unveils ToxReporter™
Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile
MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System
Genetic Biomarkers for Chronic Kidney Disease
Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer
Satoris Introduces three Novel Blood Tests
GE Healthcare Launches Discovery™ MR450
GE Healthcare in Partnership with Varian Launches Discovery MR901 (US)
Applied Biosystems and MDS Analytical Launches Novel New Mass Spectrometry Tools
Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker Panel
Thomson Reuters Introduces BIOMARKERcenter
Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker Array Kit
BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test
mtm laboratories Introduces Cervatec™ Assay
Decision Biomarkers Introduces AVANTRA Biomarker Workstation
Aureon Introduces Prostate Px® to Predict Progression and Recurrence of Prostrate cancer
VisEn Introduces a Novel Imaging Agent

9.BIOMARKERS M&A ACTIVITY

QIAGEN to Take Over Stake in Alacris Theranostics
Transgenomic Acquires Certain Businesses of Clinical Data
Caliper Life Sciences Acquires Cambridge Research & Instrumentation
Biosystems International and MicroBioChips Merge
Axela Takes Over Xceed Molecular
Accelrys Merges with Symyx Technologies
Caprion Proteomics Acquires PPD's Biomarker Division
QIAGEN Takes Over SABiosciences
Thermo Fisher Scientific Takes Over Brahms
QIAGEN Takes Over DxS
ICON Takes Over Veeda Laboratories
ID Business Solutions Takes Over InforSense
Clinical Data Acquires Avalon Pharmaceuticals
Genetix Takes Over SlidePath
Oxford Gene Technology Takes Over Sense Proteomic
Tethys Bioscience Takes Over Lipomics Technologies
QPS LLC Acquires Bio-Kinetic Clinical Applications
AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service

10.COLLABORATIONS AND AGREEMENTS

Proteome Sciences Bags Contract from Eisai
MDxHealth to Ink Partnership Agreement with Pfizer, Cancer Research Technology and Newcastle University
Takeda and Zinfandel Enter into License Agreement for AD Biomarker
Pacific Biomarkers Forges Research Deals with Two Multinational Firms
SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker
Epigenomics Enters into Collaboration with QIAGEN to Develop Colorectal Cancer Blood Tests
Vermillion Inks Agreement with Quest to Launch OVA1® in India
DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD
Prometheus Signs Agreement with The Regents of the University of California
Aushon BioSystems Enters into Partnership with LightArray Biotech
GE Healthcare Collaborates with Johnson & Johnson
ICON Enters into Strategic Alliance with Proteome Sciences
Epigenomics Inks Distribution Agreement with DATEKS
Epigenomics Inks Distribution Agreement with Pronto Diagnostics
Thermo Fisher Collaborates with Proteome Sciences
Diaceutics Teams Up with London Genetics to Develop Software Decision Tools
OncoMethylome Enters Into Agreement with GlaxoSmithKline Biologicals
SureGene Enters into Research Collaboration with Medco Research Institute
Ariadne Inks Agreement with Roswell Park Cancer Institute and Cellecta
SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers
Roche Acquires Co-exclusive License from QIAGEN
Metabolon Collaborates with Colgate-Palmolive for Periodontal Disease Biomarkers Identification
Toscana Biomarkers and Regione Toscana Enter into Grant Agreement
ACC and Roche Diagnostics Initiate Collaboration
Epigenomics Inks Distribution Agreement with DPC LEBANON
Duke Enters into Joint Venture with LabCorp for Biomarker Commercialization
HDC and SPM Enter Into Agreement with Quest Diagnostics
Toscana Biomarkers Collaborates with QuantiScientifics
Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical Diagnostics
Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences
PAREXEL Enters into Partnership with Proteome Sciences
Biocartis Inks Agreement with Royal Philips Electronics
QIAGEN Signs Agreement with Wuxi AppTec
SDIX Enters into Collaboration with Fred Hutchinson Cancer Research Center
Siemens Teams UP with EDPL to Institute Cyclotron Facility in India
ALS TDI Concluded First Phase of Collaboration with Applied Proteomics
Psynova Neurotech Teams Up with Roche for Schizophrenia Treatment Development
Minerva Biotechnologies Licenses Exclusive Marketing Rights to Clarient
Rules-Based Medicine Signs Biomarker-Driven Agreement with Covance
BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker
Epigenomics and ARUP Ink Non-Exclusive Agreement
Biosystems International Signs Licensing Agreement with Lohocla Research
Axela Signs Agreements with Micromedics and Proteome Sciences
Moffitt Cancer Center and Frantz BioMarkers Enter into Licensing Agreement
Fujirebio Diagnostics Signs Agreement with BD for Oncology Diagnostic Assays
Quest Diagnostics Bags Prostrate Cancer Test License from Epigenomics
Genedata Extends Collaboration Agreement with Roche
BioTheranostics Inks Commercialization Agreement with Lab 21 for THEROS CancerTYPE ID
Researchers Utilizes AB Sciex Qtrap 5500 System to Detect Biomarkers
Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer Test
Caprion and Applied Bioystems Partners to Accelerate Validation and Verification of Protein Biomarker
Sysmex Inks Research Partnership Deal with Epigenomics
Pharsight Inks Agreement with InforSense
AstraZeneca and Washington University Team Up to Develop Novel Methods for Alzheimer's Disease Diagnosis and Treatment

11.OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE

Genedata Installs Genedata Expressionist® Refiner MS at Victoria DPI
Genedata Deploys Genedata Expressionist® at Hospital for Sick Children
Covance Establishes New Unit for Discovery and Translation Services
The University of Liege Spins-off Targetome Business
PMDA Accepts Biomarker Panel of Critical Path’s
Clarient Obtains UK Patents for the TLE3 Biomarker
Agilent Supplies Mass Spectrometry Devices to Stemina Biomarker Discovery
Pacific Biomarkers to Launch New Logo, Marketing and Branding Initiatives
SMA Foundation Completes Biomarker Study
Genedata Offers Genedata Expressionist® to RIKEN
Chronix Biomedical Strengthens Biomarker Development Capabilities
Aureon Changes Name of Colorectal Cancer Prognostic Test
Satoris Gains Global Distribution Rights to RBM’s DiscoveryMAP™ Panel
Teva Pharmaceutical Industries to Use Biomarkers of Compugen
Genedata Provides Genedata Expressionist® System to Asubio Pharma
InforSense Aids Biomarker Discovery Process by Celera
Xennex Provides Satoris with Access to GeneCards®
IME Developed Silicon-Based Testing System for Cardiac Biomarkers

12.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (US)
Affymetrix, Inc. (US)
Agilent Technologies, Inc. (US)
Alexion Pharmaceuticals, Inc. (USA)
Beckman Coulter, Inc. (US)
Becton, Dickinson and Company (US)
Bio-Rad Laboratories, Inc. (US)
BioMerieux (France)
Bruker Corporation (US)
Caprion Proteomics, Inc. (Canada)
Clarient Inc. (US)
Compugen, Ltd. (Israel)
Correlogic Systems, Inc. (US)
DiagnoCure, Inc. (Canada)
Epigenomics AG (Germany)
GE Healthcare (UK)
Gene Logic (US)
Genedata AG (Switzerland)
Gen-Probe Inc. (US)
GlaxoSmithKline Plc. (UK)
Hitachi Medical Corporation (Japan)
Illumina, Inc. (US)
LabCorp. (US)
Life Technologies Corporation (US)
Merck & Co., Inc. (US)
Metabolon, Inc. (US)
Myriad Genetics, Inc. (US)
Novartis International AG (Switzerland)
Panacea Laboratories (US)
Pfizer, Inc. (US)
Philips Healthcare (Netherlands)
QIAGEN NV (The Netherlands)
Quest Diagnostic, Inc. (US)
Roche Diagnostics Corp. (US)
Rubicon Genomics, Inc. (US)
Rules-Based Medicine, Inc. (US)
Siemens Healthcare Diagnostics, Inc. (US)

13.GLOBAL MARKET PERSPECTIVE

Table 14. World Recent Past, Current and Future Analysis for Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 15. World 10-Year Perspective for Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 16. World Recent Past, Current and Future Analysis for Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 17. World 10-Year Perspective for Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 18. World Recent Past, Current and Future Analysis for Biomarker Technologies by Segment – Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 19. World 10-Year Perspective for Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 20. World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 21. World 10-Year Perspective for Emerging Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 22. World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Segment – Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 23. World 10-Year Perspective for Emerging Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 24. World Recent Past, Current and Future Analysis for Imaging Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 25. World 10-Year Perspective for Imaging Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 26. World Recent Past, Current and Future Analysis for Proteomics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 27. World 10-Year Perspective for Proteomics in Biomarker Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 28. World Recent Past, Current and Future Analysis for Transcriptomics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 29. World 10-Year Perspective for Transcriptomics in Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 30. World Recent Past, Current and Future Analysis for Bioinformatics in Biomarkers Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 31. World 10-Year Perspective for Bioinformatics in Biomarkers Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 32. World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 33. World 10-Year Perspective for Conventional Biomarker Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 34. World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Segment – Immunodiagnostics and Molecular Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 35. World 10-Year Perspective for Conventional Biomarker Technologies by Segment – Percentage Breakdown of Dollar Sales for Immunodiagnostics and Molecular Diagnostics Markets for Years 2008, 2011, and 2017 (includes corresponding Graph/Chart)
Table 36. World Recent Past, Current and Future Analysis for Immunodiagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 37. World 10-Year Perspective for Immunodiagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 38. World Recent Past, Current and Future Analysis for Molecular Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 39. World 10-Year Perspective for Molecular Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 40. World Recent Past, Current and Future Analysis for Other Biomarker Technologies by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 41. World 10-Year Perspective for Other Biomarker Technologie by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 42. World Recent Past, Current and Future Analysis for Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 43. World 10-Year Perspective for Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 44. World Recent Past, Current and Future Analysis for Biomarker Services by Segment– Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 45. World 10-Year Perspective for Biomarker Services by Segment – Percentage Breakdown of Dollar Sales for Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 46. World Recent Past, Current and Future Analysis for Clinical Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 47. World 10-Year Perspective for Clinical Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 48. World Recent Past, Current and Future Analysis for Specimen Preparation by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 49. World 10-Year Perspective for Specimen Preparation by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 50. World Recent Past, Current and Future Analysis for Other Biomarker Services by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 51. World 10-Year Perspective for Other Biomarker Services by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 52. World Recent Past, Current and Future Analysis for Biomarkers by Application – Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 53. World 10-Year Perspective for Biomarkers by Application – Percentage Breakdown of Dollar Sales for Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 54. World Recent Past, Current and Future Analysis for Biomarkers by Therapeutic Area – Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 55. World 10-Year Perspective for Biomarkers by Therapeutic Area – Percentage Breakdown of Dollar Sales for Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

14.THE UNITED STATES

A. Market Analysis
Current & Future Analysis
Companies Wake Up to the Growing Need for Effective Biomarkers
Biomarker Regulations in the US
Product Launches
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 56. The US Recent Past, Current and Future Analysis for Biomarkers by Segment–Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 57. The US 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

15.CANADA

A. Market Analysis
Current & Future Analysis
Product Launch
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 58. Canadian Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 59. Canadian 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

16.JAPAN

A. Market Analysis
Current & Future Analysis
Strategic Corporate Developments
Hitachi Medical Corporation – A Key Player
B. Market Analytics

Table 60. Japanese Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 61. Japanese 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17.EUROPE

A. Market Analysis
Current & Future Analysis
Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D
Biomarker Regulations in Europe
EMEA’s Experience in Pharmacogenetic Drugs - Still Nascent
Uncertain Laws Discourage VC Funding in Europe
Uncertainty Continues Among Regulators over Biomarker Validation Levels
B. Market Analytics

Table 62. European Recent Past, Current and Future Analysis for Biomarkers by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 63. European 10-Year Perspective for Biomarkers by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
Table 64. European Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 65. European 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17A.FRANCE

A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
BioMerieux (France) – A Key Player
B. Market Analytics

Table 66. French Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 67. French 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17B.GERMANY

A. Market Analysis
Current & Future Analysis
Product Launches
Strategic Corporate Development
Epigenomics AG – A Key Player
B. Market Analytics

Table 68. German Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 69. German 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17C.ITALY

A. Market Analysis
Current & Future Analysis
Strategic Corporate Developments
B. Market Analytics

Table 70. Italian Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 71. Italian 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17D.THE UNITED KINGDOM

A. Market Analysis
Current & Future Analysis
Product Launches
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 72. The UK Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 73. The UK 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

17E.REST OF EUROPE

A. Market Analysis
Current & Future Analysis
Product Launches
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 74. Rest of European Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 75. Rest of European 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

18.ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Product Launches
Strategic Corporate Developments
B. Market Analytics

Table 76. Asia-Pacific Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 77. Asia-Pacific 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Servicesz [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

19.REST OF WORLD

A. Market Analysis
Strategic Corporate Development
Compugen Ltd. (Israel)- A Key Player
B. Market Analytics

Table 78. Rest of World Recent Past, Current and Future Analysis for Biomarkers by Segment– Biomarker Technologies [Emerging Biomarker Technologies Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
Table 79. Rest of World 10-Year Perspective for Biomarkers by Segment – Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)

Total Companies Profiled: 204 (including Divisions/Subsidiaries - 210)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Ask Your Question

Biomarkers: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: